论文部分内容阅读
目的探析依帕司他联合单唾液酸四己糖神经节苷脂钠治疗糖尿病周围神经病变(DNP)的疗效及安全性。方法前瞻性选取内分泌科2013年3月至2014年3月收治的120例DNP患者,采用随机抽签法将其分为两组,每组60例。两组均行常规综合对症治疗,对照组单纯给予依帕司他片,治疗组在此基础上给予单唾液酸四己糖神经节苷脂钠。对比分析两组患者治疗效果、神经功能恢复情况以及不良反应发生情况。结果治疗组总有效率为76.67%,明显高于对照组的60.00%(χ2=3.8511,P=0.0497);治疗后两组患者正中神经、尺神经、腓总神经、胫神经运动传导速度和感觉传导速度较治疗前均明显增加(P均<0.05);治疗组改善情况明显优于对照组(P均<0.05);两组胫神经H反射潜伏期比较差异无统计学意义(P>0.05);对照组不良反应发生率(5.00%)与治疗组(3.33%)比较差异无统计学意义(P>0.05)。结论依帕司他联合单唾液酸四己糖神经节苷脂钠治疗DNP疗效显著,可改善患者神经传导速度,促进神经功能恢复,不良反应发生率低。
Objective To investigate the efficacy and safety of ipapatam combined with monosialotetrahexosyl ganglioside in the treatment of diabetic peripheral neuropathy (DNP). Methods A total of 120 patients with DNP were enrolled from March 2013 to March 2014 in the Department of Endocrinology. The patients were divided into two groups (randomized 60 cases). Patients in both groups were treated with conventional symptomatic treatment. Patients in the control group were treated with epalrestat alone. The treatment group was given monosialotetrahexosyl ganglioside sodium. Comparative analysis of two groups of patients with treatment, neurological recovery and adverse reactions. Results The total effective rate of the treatment group was 76.67%, which was significantly higher than that of the control group (χ2 = 3.8511, P = 0.0497). After the treatment, the median nerve, ulnar nerve, common peroneal nerve, (P <0.05). The improvement of the treatment group was better than that of the control group (all P <0.05). There was no significant difference in the H reflex latency between the two groups (P> 0.05). The incidence of adverse reactions in the control group (5.00%) and the treatment group (3.33%) showed no significant difference (P> 0.05). Conclusion The combination of epalrestat and monosialotetrahexosyl ganglioside in the treatment of DNP has significant curative effect, which can improve the nerve conduction velocity, promote the recovery of nerve function, and the incidence of adverse reactions is low.